Zhaoke Pharmaceutical (Guangzhou) Ltd.

Main purpose: To preliminarily evaluate the dose-effect response of fentanyl aerosol in the treatment of cancer breakthrough pain and determine the effective dose range. Secondary purpose: (1) To evaluate the safety of fentanyl aerosol. (2) To verify the basic performance stability, reliability and safety of fentanyl aerosol inhalation equipment (including: drug stimulation success rate, fingerprint recognition rate, and whether the electronic lock function is normal).

Main objectives: (1) To preliminarily evaluate the dose response of fentanyl aerosol in the treatment of cancer breakthrough pain and determine the effective dose range. (2) To evaluate the pharmacokinetic (PK) behavior of inhaled fentanyl aerosol (25ug/inhalation) in patients with tumor pain. Secondary objectives: (1) To evaluate the safety and tolerability of inhaled fentanyl aerosol in cancer patients. (2) To verify the basic performance stability, reliability and safety of the Staccato® device (including: drug stimulation success rate, fingerprint recognition rate, and whether the electronic lock function is normal). Exploratory objectives: Establish a PK-PD model to explore the PK/PD relationship of fentanyl aerosol in the treatment of cancer breakthrough pain.

Primary objective: To evaluate the safety and tolerability of a single oral dose of Noxaban tablets in Chinese healthy subjects. Secondary objectives: To evaluate the pharmacokinetic (PK) properties of a single oral dose of Noxaban tablets in Chinese healthy subjects; To evaluate the pharmacodynamic (PD) properties of a single oral dose of Noxaban tablets in Chinese healthy subjects; To analyze the correlation between the pharmacokinetics (PK) and pharmacodynamics (PD) of Noxaban tablets; To analyze the metabolites of Noxaban tablets in human plasma and urine